Following her April 2026 guilty plea, the U.S. Attorney’s Office for the District of Massachusetts reported that Rebecca Fadanelli was ordered to serve two years of supervised release and pay $1 million in restitution and an additional $1 million in forfeiture.
U.S. Attorney’s Office Details Sentencing in Counterfeit Injection Case
On September 2, 2026, Rebecca Fadanelli, owner of Skin Beaute Med Spa, was sentenced in federal court in Boston to 46 months in prison after pleading guilty to charges involving counterfeit injectable products. Federal prosecutors stated that Fadanelli performed thousands of cosmetic injections while not licensed to administer prescription drugs or devices and purchased counterfeit injectables from China and Brazil, placing practitioner licensure and injectable product sourcing at the center of the case.
Federal Case Timeline and Sentencing Details
The September sentencing follows Rebecca Fadanelli’s April 2026 guilty plea in a case involving counterfeit injectable products and unlicensed injection procedures at Skin Beaute Med Spa locations in Randolph and South Easton, Massachusetts.
Fadanelli pleaded guilty on April 7, 2026, to:
- Four counts of importing merchandise contrary to law
- Two counts of selling or dispensing a counterfeit drug
- Two counts of selling or dispensing a counterfeit device
The federal investigation began after a complaint to the FDA involving a lip filler procedure. The October 2024 criminal complaint described U.S. Customs and Border Protection seizures, an undercover operation, business-record reviews, and June 2024 searches of both Skin Beaute Med Spa locations. The complaint stated that Fadanelli was registered as an aesthetician in Massachusetts and that investigators found no indication she was authorized to prescribe, dispense, or administer prescription drugs or devices through injections.
Federal authorities arrested Fadanelli on November 1, 2024. A sentencing hearing originally scheduled for July 1, 2026, was later moved to September 2, when U.S. District Judge Julia E. Kobick imposed the sentence.
The sentencing terms include:
- Prison sentence: Fadanelli was sentenced to 46 months in federal prison.
- Supervised release: She was sentenced to two years of supervised release following imprisonment.
- Restitution: The court ordered Fadanelli to pay $1,001,562 in restitution.
- Forfeiture: The court ordered forfeiture of an additional $1,001,562.
The U.S. Attorney’s Office also reported that business records showed more than 2,700 botulinum toxin and dermal filler procedures between approximately March 2021 and June 2024. More than 900 clients paid a combined total exceeding $1 million, and multiple clients were hospitalized or required follow-up medical treatment after experiencing adverse effects following injections.
Source Attribution
According to a September 4, 2026, press release from the U.S. Attorney’s Office for the District of Massachusetts, Rebecca Fadanelli was sentenced to 46 months in federal prison following her April guilty plea in the counterfeit injection case.
Compliance Context for Injectable Products, Provider Licensure, and FDA Oversight
This federal case highlights practitioner licensure, injectable product sourcing, and federal drug and device requirements. The U.S. Attorney’s Office stated that Fadanelli was registered as an aesthetician and was not licensed to perform injections or administer prescription drugs. Massachusetts Board policy separately prohibits aestheticians from performing injections, including Botox and dermal filler injections.
Key compliance details of the case include:
- Provider authority: Federal prosecutors stated that Fadanelli falsely represented herself as a licensed nurse while performing injectable procedures.
- Product sourcing: The case involved counterfeit Botox, Sculptra, Restylane, and Juvéderm imported from China and Brazil. Manufacturer records cited in the criminal complaint showed no indication that Fadanelli or Skin Beaute Med Spa purchased authentic Botox, Juvéderm, or Sculptra through the identified manufacturers or distributors.
- Federal drug and device oversight: The complaint identifies Botox as a prescription drug and Sculptra and Juvéderm as prescription medical devices. Investigators determined the products seized during the investigation were misbranded, unapproved, or counterfeit.
- Import and enforcement activity: U.S. Customs and Border Protection seized multiple international shipments connected to Fadanelli or Skin Beaute Med Spa. The investigation also involved the FDA Office of Criminal Investigations, the Massachusetts Attorney General’s Office, and local law enforcement.
Injectable services involve state scope-of-practice and provider-licensure requirements, FDA oversight of prescription injectable products, and product-sourcing requirements.
Similar concerns have appeared in other aesthetic enforcement matters. A June 2026 Houston case involving alleged unlicensed lip filler injections centered on practitioner licensing, while an April 2026 Utah federal indictment involving non-FDA-approved peptides imported from China addressed product sourcing and federal drug requirements. For Med Spa and aesthetic operators, these cases show how injectable services can involve both state licensing requirements and federal oversight of drugs, devices, and imported products.
Practical Implications for Med Spa and Aesthetic Operators
- Verify practitioner licensure and scope-of-practice requirements under applicable state law before offering injectable services.
- Source prescription injectable products through authorized manufacturers and licensed distributors with verifiable supply chains.
- Review applicable FDA requirements for prescription injectable products and confirm services align with federal drug and product requirements.
- Maintain documentation for injectable product procurement, storage, lot information, and administration.
- Establish compliant procedures for product sourcing, patient evaluation, and delivery of injectable services.
What to Watch Next
As of this reporting, Fadanelli has been sentenced to 46 months in federal prison following her April 2026 guilty plea. The FDA Office of Criminal Investigations and U.S. Customs and Border Protection investigated the case, with assistance from state and local authorities. Further federal or state updates may provide additional context for Med Spa and aesthetic operators regarding provider licensure, injectable product sourcing, and prescription injectable services.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Legal Gavel & Open Law Book” by howtostartablogonline.net, via Wikimedia Commons, licensed under CC BY 2.0.
